Join Tom Barker and Caroline Farrell for an in-depth webinar examining the rapidly evolving regulatory environment surrounding Medicare drug pricing. This session will provide life sciences innovators, pharmaceutical manufacturers, healthcare providers and industry stakeholders with practical guidance on recent policy developments and their implications for compliance and business operations.

The panel will discuss recent developments under the Medicare Drug Price Negotiation Program, including the IPAY 2028 guidance, drugs selected for price negotiation, and updates on the 340B program. We will also examine the administration’s Medicare Mandatory Drug Pricing Models, specifically the GLOBE Model for Part B drugs and the GUARD Model for Part D drugs.

The session will address the TrumpRx direct-to-consumer drug purchasing initiative and the OIG’s Special Advisory Bulletin on Anti-Kickback Statute implications for manufacturer-to-patient sales. The speakers will conclude with a discussion of recent pharmaceutical manufacturer deals with the administration and tariff-related developments.

CLE credit for this course is available in New York and California. This program is offering 1.0 Areas of Professional Practice CLE credit in NY, and 1.0 General CLE credit in CA. The program is appropriate for both newly admitted attorneys and experienced attorneys. Please contact us for details.